Is AbbVie the Best Dividend King to Buy in September?
It is certainly a good Dividend King to buy in September.
Dividend Kings are some of the most reliable income stocks available. These are companies that have raised their dividends for at least 50 continuous years. However, not all Dividend Kings are created equal. While some, like Hormel Foods (NYSE: HRL), are facing difficulties, others such as Johnson & Johnson (NYSE: JNJ) are posting strong financials.
AbbVie (NYSE: ABBV), a major pharmaceutical company, stands out as a popular Dividend King with a lot to offer. The question remains - is AbbVie the best Dividend King to invest in this month? Let's take a closer look. Image source: The Motley Fool. AbbVie holds its Dividend King status due to its history as a division of Abbott Laboratories (NYSE: ABT).
When combining the time it spent as Abbott's subsidiary, AbbVie has increased its payouts for 54 straight years. Nevertheless, AbbVie has been exceptional in its own right since separating from Abbott in 2013. AbbVie has matched Abbott's dividend growth rates since 2013 and has generated superior returns during this period.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
